Regulatory filings disclosed Monday show significant insider stock sales by top executives at Datadog and United Therapeutics, totaling over $21 million, while a major shareholder increased its stake in Energizer Holdings.
Alkermes (ALKS) shares fell after its Q2 2026 earnings report, as a full-year revenue guidance midpoint that fell short of analyst expectations overshadowed beats on quarterly earnings and sales.
Shares of Cullinan Therapeutics gained after the company announced it would launch a potentially registrational Phase 2 trial for its leukemia drug, CLN-049, following constructive feedback from the FDA.
Shares of the auto retailer climbed after it reported second-quarter adjusted earnings that surpassed Wall Street expectations, offsetting a miss on revenue and a decline in net income.
Contract research organization ICON saw its stock surge in pre-market trading after announcing a multi-year collaboration with AI firm Anthropic to enhance its clinical trial platform.
The bioprocessing firm's stock rallied after it posted second-quarter earnings and revenue that topped analyst estimates and boosted its annual forecast, citing strong order momentum.
JPMorgan analysts highlight the healthcare sector as an overlooked opportunity, citing its deep underperformance, attractive valuations, and durable growth prospects in a market heavily concentrated on AI.
Shares of the biopharmaceutical company jumped after interim Phase 1b trial data for its Alzheimer's candidate, PMN310, revealed zero cases of a key side effect, brain swelling, boosting investor confidence.
CEO Ola Kaellenius addressed concerns about potential U.S. market restrictions, stating the company will make any necessary adjustments to safeguard its operations as Washington scrutinizes its major Chinese investors.
